Age, Gender, and Cancer but Not Neurodegenerative and Cardiovascular Diseases Strongly Modulate Systemic Effect of the Apolipoprotein E4 Allele on Lifespan
Enduring interest in the Apolipoprotein E (ApoE) polymorphism is ensured by its evolutionary-driven uniqueness in humans and its prominent role in geriatrics and gerontology. We use large samples of longitudinally followed populations from the Framingham Heart Study (FHS) original and offspring cohorts and the Long Life Family Study (LLFS) to investigate gender-specific effects of the ApoE4 allele on human survival in a wide range of ages from midlife to extreme old ages, and the sensitivity of these effects to cardiovascular disease (CVD), cancer, and neurodegenerative disorders (ND). The analyses show that women's lifespan is more sensitive to the e4 allele than men's in all these populations. A highly significant adverse effect of the e4 allele is limited to women with moderate lifespan of about 70 to 95 years in two FHS cohorts and the LLFS with relative risk of death RR = 1.48 (p = 3.6×10−6) in the FHS cohorts. Major human diseases including CVD, ND, and cancer, whose risks can be sensitive to the e4 allele, do not mediate the association of this allele with lifespan in large FHS samples. Non-skin cancer non-additively increases mortality of the FHS women with moderate lifespans increasing the risks of death of the e4 carriers with cancer two-fold compared to the non-e4 carriers, i.e., RR = 2.07 (p = 5.0×10−7). The results suggest a pivotal role of non-sex-specific cancer as a nonlinear modulator of survival in this sample that increases the risk of death of the ApoE4 carriers by 150% (p = 5.3×10−8) compared to the non-carriers. This risk explains the 4.2 year shorter life expectancy of the e4 carriers compared to the non-carriers in this sample. The analyses suggest the existence of age- and gender-sensitive systemic mechanisms linking the e4 allele to lifespan which can non-additively interfere with cancer-related mechanisms.
Vyšlo v časopise:
Age, Gender, and Cancer but Not Neurodegenerative and Cardiovascular Diseases Strongly Modulate Systemic Effect of the Apolipoprotein E4 Allele on Lifespan. PLoS Genet 10(1): e32767. doi:10.1371/journal.pgen.1004141
Kategorie:
Research Article
prolekare.web.journal.doi_sk:
https://doi.org/10.1371/journal.pgen.1004141
Souhrn
Enduring interest in the Apolipoprotein E (ApoE) polymorphism is ensured by its evolutionary-driven uniqueness in humans and its prominent role in geriatrics and gerontology. We use large samples of longitudinally followed populations from the Framingham Heart Study (FHS) original and offspring cohorts and the Long Life Family Study (LLFS) to investigate gender-specific effects of the ApoE4 allele on human survival in a wide range of ages from midlife to extreme old ages, and the sensitivity of these effects to cardiovascular disease (CVD), cancer, and neurodegenerative disorders (ND). The analyses show that women's lifespan is more sensitive to the e4 allele than men's in all these populations. A highly significant adverse effect of the e4 allele is limited to women with moderate lifespan of about 70 to 95 years in two FHS cohorts and the LLFS with relative risk of death RR = 1.48 (p = 3.6×10−6) in the FHS cohorts. Major human diseases including CVD, ND, and cancer, whose risks can be sensitive to the e4 allele, do not mediate the association of this allele with lifespan in large FHS samples. Non-skin cancer non-additively increases mortality of the FHS women with moderate lifespans increasing the risks of death of the e4 carriers with cancer two-fold compared to the non-e4 carriers, i.e., RR = 2.07 (p = 5.0×10−7). The results suggest a pivotal role of non-sex-specific cancer as a nonlinear modulator of survival in this sample that increases the risk of death of the ApoE4 carriers by 150% (p = 5.3×10−8) compared to the non-carriers. This risk explains the 4.2 year shorter life expectancy of the e4 carriers compared to the non-carriers in this sample. The analyses suggest the existence of age- and gender-sensitive systemic mechanisms linking the e4 allele to lifespan which can non-additively interfere with cancer-related mechanisms.
Zdroje
1. McIntoshAM, BennettC, DicksonD, AnestisSF, WattsDP, et al. (2012) The Apolipoprotein E (APOE) Gene Appears Functionally Monomorphic in Chimpanzees (Pan troglodytes). PLoS One 7: e47760.
2. FullertonSM, ClarkAG, WeissKM, NickersonDA, TaylorSL, et al. (2000) Apolipoprotein E variation at the sequence haplotype level: implications for the origin and maintenance of a major human polymorphism. Am J Hum Genet 67: 881–900.
3. CorderEH, SaundersAM, StrittmatterWJ, SchmechelDE, GaskellPC, et al. (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261: 921–923.
4. BertramL, McQueenMB, MullinK, BlackerD, TanziRE (2007) Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat Genet 39: 17–23.
5. FarrerLA, CupplesLA, HainesJL, HymanB, KukullWA, et al. (1997) Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 278: 1349–1356.
6. SongY, StampferMJ, LiuS (2004) Meta-analysis: apolipoprotein E genotypes and risk for coronary heart disease. Ann Intern Med 141: 137–147.
7. WilsonPW, SchaeferEJ, LarsonMG, OrdovasJM (1996) Apolipoprotein E alleles and risk of coronary disease. A meta-analysis. Arterioscler Thromb Vasc Biol 16: 1250–1255.
8. KulminskiAM, CulminskayaI, ArbeevKG, UkraintsevaSV, StallardE, et al. (2013) The role of lipid-related genes, aging-related processes, and environment in healthspan. Aging Cell 12: 237–246.
9. SoerensenM, DatoS, TanQ, ThinggaardM, KleindorpR, et al. (2013) Evidence from case-control and longitudinal studies supports associations of genetic variation in APOE, CETP, and IL6 with human longevity. Age (Dordr) 35: 487–500.
10. ChristensenK, JohnsonTE, VaupelJW (2006) The quest for genetic determinants of human longevity: challenges and insights. Nat Rev Genet 7: 436–448.
11. NapolioniV, GianniP, CarpiFM, PredazziIM, LucariniN (2011) APOE haplotypes are associated with human longevity in a Central Italy population: evidence for epistasis with HP 1/2 polymorphism. Clin Chim Acta 412: 1821–1824.
12. DeelenJ, BeekmanM, UhHW, HelmerQ, KuningasM, et al. (2011) Genome-wide association study identifies a single major locus contributing to survival into old age; the APOE locus revisited. Aging Cell 10: 686–698.
13. NebelA, KleindorpR, CaliebeA, NothnagelM, BlancheH, et al. (2011) A genome-wide association study confirms APOE as the major gene influencing survival in long-lived individuals. Mechanisms of Ageing and Development 132: 324–330.
14. JazwinskiSM, KimS, DaiJ, LiL, BiX, et al. (2010) HRAS1 and LASS1 with APOE are associated with human longevity and healthy aging. Aging Cell 9: 698–708.
15. EwbankDC (2004) The APOE gene and differences in life expectancy in Europe. J Gerontol A Biol Sci Med Sci 59: 16–20.
16. LittleDM, CrooksVC, PetittiDB, ChiuV, SchellenbergGD, et al. (2009) Mortality, dementia, and apolipoprotein E genotype in elderly white women in the United States. J Am Geriatr Soc 57: 231–236.
17. RosvallL, RizzutoD, WangHX, WinbladB, GraffC, et al. (2009) APOE-related mortality: effect of dementia, cardiovascular disease and gender. Neurobiol Aging 30: 1545–1551.
18. JacobsenR, MartinussenT, ChristiansenL, JeuneB, Andersen-RanbergK, et al. (2010) Increased effect of the ApoE gene on survival at advanced age in healthy and long-lived Danes: two nationwide cohort studies. Aging Cell 9: 1004–1009.
19. KulminskiAM, CulminskayaI, UkraintsevaSV, ArbeevKG, ArbeevaL, et al. (2011) Trade-off in the effects of the apolipoprotein E polymorphism on the ages at onset of CVD and cancer influences human lifespan. Aging Cell 10: 533–541.
20. SchwankeCH, da CruzIB, LealNF, ScheibeR, MoriguchiY, et al. (2002) Analysis of the association between apolipoprotein E polymorphism and cardiovascular risk factors in an elderly population with longevity. Arq Bras Cardiol 78: 561–579.
21. RuiuG, CassaderM, GambinoR, AlemannoN, DemichieliF, et al. (1995) Apolipoprotein E allele frequencies in an Italian population: relation to age and lipid profile. Aging (Milano) 7: 185–189.
22. GalinskyD, TysoeC, BrayneCE, EastonDF, HuppertFA, et al. (1997) Analysis of the apo E/apo C-I, angiotensin converting enzyme and methylenetetrahydrofolate reductase genes as candidates affecting human longevity. Atherosclerosis 129: 177–183.
23. PanzaF, FrisardiV, CapursoC, D'IntronoA, ColaciccoAM, et al. (2009) Apolipoprotein E, dementia, and human longevity. J Am Geriatr Soc 57: 740–742.
24. LewisSJ, BrunnerEJ (2004) Methodological problems in genetic association studies of longevity–the apolipoprotein E gene as an example. Int J Epidemiol 33: 962–970.
25. FinchCE (2012) Evolution of the human lifespan, past, present, and future: phases in the evolution of human life expectancy in relation to the inflammatory load. Proc Am Philos Soc 156: 9–44.
26. DrenosF, KirkwoodTB (2010) Selection on alleles affecting human longevity and late-life disease: the example of apolipoprotein E. PLoS One 5: e10022.
27. CharlesworthB (1996) Evolution of senescence: Alzheimer's disease and evolution. Curr Biol 6: 20–22.
28. MartinGM (1999) APOE alleles and lipophylic pathogens. Neurobiol Aging 20: 441–443.
29. FinchCE (2010) Evolution in health and medicine Sackler colloquium: Evolution of the human lifespan and diseases of aging: roles of infection, inflammation, and nutrition. Proc Natl Acad Sci U S A 107 Suppl 1: 1718–1724.
30. KuhlmannI, MinihaneAM, HuebbeP, NebelA, RimbachG (2010) Apolipoprotein E genotype and hepatitis C, HIV and herpes simplex disease risk: a literature review. Lipids Health Dis 9: 8.
31. SchupfN, BarralS, PerlsT, NewmanA, ChristensenK, et al. (2013) Apolipoprotein E and familial longevity. Neurobiol Aging 34: 1287–1291.
32. EwbankDC (2002) Mortality differences by APOE genotype estimated from demographic synthesis. Genet Epidemiol 22: 146–155.
33. YashinAI, WuD, ArbeevKG, UkraintsevaSV (2012) Polygenic Effects of Common Single-Nucleotide Polymorphisms on Life Span: When Association Meets Causality. Rejuvenation Res 15: 381–94.
34. Day-WilliamsAG, ZegginiE (2011) The effect of next-generation sequencing technology on complex trait research. Eur J Clin Invest 41: 561–567.
35. McClellanJ, KingMC (2010) Genetic heterogeneity in human disease. Cell 141: 210–217.
36. KulminskiAM (2013) Unraveling genetic origin of aging-related traits: evolving concepts. Rejuvenation Res 16: 304–312.
37. CamposM, EdlandSD, PeavyGM (2013) Exploratory study of apolipoprotein E epsilon4 genotype and risk of Alzheimer's disease in Mexican Hispanics. J Am Geriatr Soc 61: 1038–1040.
38. KulminskiAM, CulminskayaI, ArbeevKG, UkraintsevaSV, ArbeevaL, et al. (2013) Trade-off in the effect of the APOE gene on the ages at onset of cardiocascular disease and cancer across ages, gender, and human generations. Rejuvenation Res 16: 28–34.
39. NewmanAB, SachsMC, ArnoldAM, FriedLP, KronmalR, et al. (2009) Total and cause-specific mortality in the cardiovascular health study. J Gerontol A Biol Sci Med Sci 64: 1251–1261.
40. SaadatM (2012) Apolipoprotein E (APOE) Polymorphisms and Susceptibility to Breast Cancer: A Meta-Analysis. Cancer Res Treat 44: 121–126.
41. ChenYC, PohlG, WangTL, MorinPJ, RisbergB, et al. (2005) Apolipoprotein E is required for cell proliferation and survival in ovarian cancer. Cancer Res 65: 331–337.
42. SakashitaK, TanakaF, ZhangX, MimoriK, KamoharaY, et al. (2008) Clinical significance of ApoE expression in human gastric cancer. Oncol Rep 20: 1313–1319.
43. SlatteryML, SweeneyC, MurtaughM, MaKN, PotterJD, et al. (2005) Associations between apoE genotype and colon and rectal cancer. Carcinogenesis 26: 1422–1429.
44. RockwoodK, NassarB, MitnitskiA (2008) Apolipoprotein E-polymorphism, frailty and mortality in older adults. J Cell Mol Med 12: 2754–2761.
45. Jofre-MonsenyL, MinihaneAM, RimbachG (2008) Impact of apoE genotype on oxidative stress, inflammation and disease risk. Mol Nutr Food Res 52: 131–145.
46. de MagalhaesJP (2013) How ageing processes influence cancer. Nat Rev Cancer 13: 357–365.
47. ZetterbergH, PalmerM, RickstenA, PoirierJ, PalmqvistL, et al. (2002) Influence of the apolipoprotein E epsilon4 allele on human embryonic development. Neurosci Lett 324: 189–192.
48. BecherJC, KeelingJW, McIntoshN, WyattB, BellJ (2006) The distribution of apolipoprotein E alleles in Scottish perinatal deaths. J Med Genet 43: 414–418.
49. OriaRB, PatrickPD, BlackmanJA, LimaAA, GuerrantRL (2007) Role of apolipoprotein E4 in protecting children against early childhood diarrhea outcomes and implications for later development. Med Hypotheses 68: 1099–1107.
50. WozniakMA, ItzhakiRF, FaragherEB, JamesMW, RyderSD, et al. (2002) Apolipoprotein E-epsilon 4 protects against severe liver disease caused by hepatitis C virus. Hepatology 36: 456–463.
51. FabrisC, ToniuttoP, BitettoD, MinisiniR, SmirneC, et al. (2005) Low fibrosis progression of recurrent hepatitis C in apolipoprotein E epsilon4 carriers: relationship with the blood lipid profile. Liver Int 25: 1128–1135.
52. VitekMP, BrownCM, ColtonCA (2009) APOE genotype-specific differences in the innate immune response. Neurobiol Aging 30: 1350–1360.
53. MalaguarneraM, CristaldiE, RomanoG, MalaguarneraL (2012) Autoimmunity in the elderly: Implications for cancer. J Cancer Res Ther 8: 520–527.
54. BergmanA, AtzmonG, YeK, MacCarthyT, BarzilaiN (2007) Buffering mechanisms in aging: a systems approach toward uncovering the genetic component of aging. PLoS Comput Biol 3: e170.
55. GovindarajuDR, CupplesLA, KannelWB, O'DonnellCJ, AtwoodLD, et al. (2008) Genetics of the Framingham Heart Study population. Adv Genet 62: 33–65.
56. SplanskyGL, CoreyD, YangQ, AtwoodLD, CupplesLA, et al. (2007) The Third Generation Cohort of the National Heart, Lung, and Blood Institute's Framingham Heart Study: design, recruitment, and initial examination. Am J Epidemiol 165: 1328–1335.
57. CupplesLA, Heard-CostaN, LeeM, AtwoodLD (2009) Genetics Analysis Workshop 16 Problem 2: the Framingham Heart Study data. BMC Proc 3 Suppl 7: S3.
58. DriverJA, BeiserA, AuR, KregerBE, SplanskyGL, et al. (2012) Inverse association between cancer and Alzheimer's disease: results from the Framingham Heart Study. British Medical Journal 344: e1442.
59. LahozC, SchaeferEJ, CupplesLA, WilsonPW, LevyD, et al. (2001) Apolipoprotein E genotype and cardiovascular disease in the Framingham Heart Study. Atherosclerosis 154: 529–537.
60. MyersRH, SchaeferEJ, WilsonPW, D'AgostinoR, OrdovasJM, et al. (1996) Apolipoprotein E epsilon4 association with dementia in a population-based study: The Framingham study. Neurology 46: 673–677.
61. SebastianiP, HadleyEC, ProvinceM, ChristensenK, RossiW, et al. (2009) A family longevity selection score: ranking sibships by their longevity, size, and availability for study. Am J Epidemiol 170: 1555–1562.
62. PedersenCB, GotzscheH, MollerJO, MortensenPB (2006) The Danish Civil Registration System. A cohort of eight million persons. Dan Med Bull 53: 441–449.
63. YashinAI, ArbeevKG, KulminskiA, BoreckiI, ChristensenK, et al. (2010) “Predicting” parental longevity from offspring endophenotypes: data from the Long Life Family Study (LLFS). Mech Ageing Dev 131: 215–222.
64. EichnerJE, DunnST, PerveenG, ThompsonDM, StewartKE, et al. (2002) Apolipoprotein E polymorphism and cardiovascular disease: a HuGE review. Am J Epidemiol 155: 487–495.
65. MantonKG, StallardE (1980) Mortality of the chronically impaired. Demography 17: 189–206.
Štítky
Genetika Reprodukčná medicínaČlánok vyšiel v časopise
PLOS Genetics
2014 Číslo 1
- Je „freeze-all“ pro všechny? Odborníci na fertilitu diskutovali na virtuálním summitu
- Gynekologové a odborníci na reprodukční medicínu se sejdou na prvním virtuálním summitu
Najčítanejšie v tomto čísle
- GATA6 Is a Crucial Regulator of Shh in the Limb Bud
- Large Inverted Duplications in the Human Genome Form via a Fold-Back Mechanism
- Genome Sequencing Highlights the Dynamic Early History of Dogs
- Down-Regulation of Rad51 Activity during Meiosis in Yeast Prevents Competition with Dmc1 for Repair of Double-Strand Breaks